AIM ImmunoTech Inc. announced an agreement with the PPD?? clinical research business of Thermo Fisher Scientific to design AIM's anticipated Phase 3 clinical trial in the use of the Company's drug Ampligen in the treatment of late-stage pancreatic cancer. AIM recently published an updated corporate presentation that emphasizes the Company's priority goal of a new drug approval for Ampligen in the treatment of pancreatic cancer.
The presentation details AIM's research and development work in pancreatic cancer; how Ampligen is believed to work in the treatment of pancreatic Cancer; and why AIM believes that pancreatic cancer research and development holds the most potential for AIM's stockholders. AIM has thus far reported positive progress in Progression-Free Survival ("PFS"), Overall Survival ("OS") and safety in the DURIPANC study, which is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion. The clinical trial is a joint collaboration between AIM, AstraZeneca and Erasmus Medical Center ("Erasmus MC") in the Netherlands.
